Evidence map›Paper›PMID 34962077›Full record

ArticlePharmaceutical statistics2022

Empirical likelihood confidence interval for sensitivity to the early disease stage.

Husneara Rahman, Yichuan Zhao, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Pharmaceutical statistics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Husneara RahmanDepartment of Mathematics and Statistics, Georgia State University, Atlanta, Georgia, USA.
Yichuan ZhaoDepartment of Mathematics and Statistics, Georgia State University, Atlanta, Georgia, USA.ORCID 0000-0002-5069-1968
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
CIHRNIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904
6 · The paper itself

Abstract

Disease status can naturally be classified into three or more ordinal stages rather than just being binary stages. Many works have been done for the estimation and inference procedure regarding three ordinal disease stages, which are non-disease, early disease, and full disease stages. The early disease stage can be very important for therapeutic intervention and prevention potentiality. As a diagnostic measure, sensitivity to the early disease stage is often used. In this article, we propose confidence intervals for the sensitivity to early disease stage based on given target specificity for non-disease stage and target sensitivity to full disease stage using both empirical likelihood (EL) and adjusted EL procedures. We compare the performance of the proposed EL confidence intervals with other procedures in our simulation study. The proposed procedures are further applied to Alzheimer's Disease Neuroimaging Initiative data set.

Indexed as

Alzheimer DiseaseComputer SimulationConfidence IntervalsHumansLikelihood Functionsconfidence intervalearly disease stageempirical likelihoodordinal disease stagessensitivity

Identifiers

PMID34962077
PMCPMC9050820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.